Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Circio Holding ASA

Headquarters: Oslo, Norway
Year Founded: 2010
Status: Public
Industry Sector: HealthTechnology
CEO: Erik Digman Wiklund, PhD
Number Of Employees: 11
Enterprise Value: $13,369,501
PE Ratio: 0.65
Exchange/Ticker 1: OSE:CRNA
Exchange/Ticker 2: N/A
Latest Market Cap: $4,307,269

BioCentury | Jan 11, 2025
Management Tracks

Faces in new places ahead of JPM: Rubin joining Guggenheim

Week’s management moves include new venture partners at Frazier and updates from Beigene, Intellia and more
BioCentury | Jan 10, 2025
Management Tracks

Odyssey hires Jason Haas as CFO

Plus: CMO changes at Centessa, Lifordi, Rapport and Gemma, and updates from Peptone, Labgenius, Mitorx and more
BioCentury | Apr 23, 2024
Deals

Deals report: Two Japanese pharmas set up local biotech incubator

Plus: Takeda licenses immuno-oncology program from Kumquat, and deals for Ipsen-Skyhawk, Boehringer-Ochre and more 
BioCentury | Mar 26, 2024
Deals

Deals Report: Week’s M&A includes AZ-Fusion, Novo Nordisk-Cardior

Plus: Intellia deciding to step back from co-developing Factor-IX therapy with Regeneron and GSK returns Sosei’s GPR35 agonist after deprioritization
BioCentury | Aug 17, 2023
Product Development

Emerging circular RNA field split on what to deliver and how to deliver it

The rising therapeutic modality is more durable than linear mRNA, promising efficacy and manufacturing advantages
BioCentury | Jun 21, 2023
Management Tracks

Jonathan Mow named CEO at Veralox

Plus: Ottesen becomes CMO at Adcendo, and updates from Splice Bio, Shape, C4 and more
Items per page:
1 - 6 of 6